Zimmer Biomet Holdings (ZBH) is back in focus after the company lifted its 2026 share repurchase expectations to US$1.0b and raised its adjusted earnings per share forecast, drawing fresh attention to the stock.

The share price has picked up in the very short term, with a 1-day share price return of 1.27% and a 7-day gain of 5.18%. However, this follows a 30-day share price return down 11.69% and a 1-year total shareholder return down 11.69%. This suggests recent buyback and earnings guidance news is improving sentiment after a weaker multi year run.

If this kind of earnings and buyback story has your attention, it could be a good moment to look at other potential opportunities through our healthcare focused AI stock screener, including 32 healthcare AI stocks

With Zimmer Biomet trading at US$83.70, carrying an intrinsic value estimate at a 58% discount and sitting below the average analyst price target, the key question is whether this is a genuine opportunity or if the market already reflects future growth.

Most Popular Narrative: 18.7% Undervalued

Zimmer Biomet’s most followed narrative pegs fair value at $102.95 versus the last close at $83.70, framing the current price as a discount that hinges heavily on execution in earnings and share repurchases.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Curious what sits behind that premium mix story and recurring revenue push? The narrative leans on targeted procedure growth, richer margins and a future earnings profile that only lines up if several moving parts click together.

Result: Fair Value of $102.95 (UNDERVALUED)

However, there is still a real risk that flat pricing and tighter reimbursement, or delays and hiccups integrating acquisitions, could pressure margins and upset the premium mix story.

Next Steps

With both clear concerns and genuine bright spots in this story, it makes sense to review the numbers yourself and move quickly to form your own stance. You can start with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Zimmer Biomet has sharpened your focus, do not stop here. Broaden your watchlist with other clear, data driven ideas before the next move passes you by.

• Target potential upside by scanning for companies that combine quality fundamentals with a favorable price using our 51 high quality undervalued stocks.
• Prioritize resilience and sleep easier at night by checking companies that pass tough balance sheet and fundamentals checks with the solid balance sheet and fundamentals stocks screener (45 results).
• Get ahead of the crowd by reviewing a screener containing 21 high quality undiscovered gems that may not yet be on most investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.